vimarsana.com

Page 2 - Sandeep Kulkarni News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tourmaline Bio, Inc s (NASDAQ:TRML) top owners are retail investors with 58% stake, while 11% is held by institutions

Key Insights Significant control over Tourmaline Bio by retail investors implies that the general public has more power.

Sandeep kulkarniCompany ownershipPfizer incTourmaline bio incHydra llcPublic company ownershipTourmaline bioDeep track capitalPrivate companiesRetail investorsHare registry

Tourmaline Bio Stock: Time For A Pause (NASDAQ:TRML)

Tourmaline Bio Stock: Time For A Pause (NASDAQ:TRML)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkParvinder thiaraDante alighieriNovo nordiskSandeep kulkarniCompany overviewTourmaline bio incInhibition company websitePipeline company websiteTourmaline bioNew york cityTalaris therapeuticsAnalyst commentary

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026 .

Yung chyungSandeep kulkarniTourmaline bio incUs food drug administrationExchange commissionDrug administrationChief executive officerChief medical officerTourmaline bioPrivate securities litigation reform actQuarterly report

Tourmaline Bio (TRML) Appoints Dr Clay Siegall as Board Chair

Tourmaline Bio (TRML) Appoints Dr Clay Siegall as Board Chair
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Clay siegallSandeep kulkarniPfizer incGeorge washington universityNational cancer instituteBristol myers squibbUniversity of marylandSeagen incBoard of immunone incTourmaline bio incTourmaline bioChief executive officerNational cancer

Tourmaline Bio Appoints Dr Clay Siegall as Chairman of the Board

NEW YORK, Dec. 14, 2023 Tourmaline Bio, Inc. , a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering.

Clay siegallSandeep kulkarniBristol myers squibbSeagen incUniversity of marylandPfizer incGeorge washington universityNational cancer instituteTourmaline bio incBoard of immunone incExchange commissionChief executive officerNational cancerTourmaline bioThyroid eye diseasePrivate securities litigation reform act

vimarsana © 2020. All Rights Reserved.